Search tips
Search criteria 


Logo of jrsocmedLink to Publisher's site
J R Soc Med. 1993 May; 86(5): 261–263.
PMCID: PMC1294000

The effectiveness of low dose slow release aspirin as an antiplatelet agent.


An open, randomized, parallel group study of three different aspirin preparations was carried out. The objective of this study was to compare their ability to inhibit the production of thromboxane A2 (measured as thromboxane B2 [TXB2]) from platelets. Three aspirin preparations were studied: Acetard 300 mg, Acetard 100 mg and Platet 100 mg. The study was conducted in 45 healthy adult volunteers and treatment continued once daily for 7 days. The results of the TXB2 assay show that the administration of all three treatment preparations produced a rapid drop in TXB2 levels of all volunteers. The baseline TXB2 level was reduced by 95% for all groups by day 3. Analysis by day showed a significant difference (P < 0.05) between treatments at day 1, with Acetard 100 mg having higher TXB2 levels than the other two groups. Analysis of changes from baseline showed a significant reduction (P < 0.05) in TXB2 levels at Days 1 to 14 for all three groups. Platelet aggregation also showed a significant reduction, being reduced to 10% of control at 7 days. It then reverted back to baseline by 28 days for all treatment groups. In conclusion, low dose aspirin is very effective as an antiplatelet agent and in a slow release form loses none of its patency.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982 Jun;69(6):1366–1372. [PMC free article] [PubMed]
  • Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988 Jan 30;296(6618):313–316. [PMC free article] [PubMed]
  • Weksler BB, Pett SB, Alonso D, Richter RC, Stelzer P, Subramanian V, Tack-Goldman K, Gay WA., Jr Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med. 1983 Apr 7;308(14):800–805. [PubMed]
  • Preston FE, Greaves M, Jackson CA, Stoddard CJ. Low-dose aspirin inhibits platelet and venous cyclo-oxygenase in man. Thromb Res. 1982 Aug 15;27(4):477–484. [PubMed]
  • Weiss HJ, Aledort LM. Impaired platelet-connective-tissue reaction in man after aspirin ingestion. Lancet. 1967 Sep 2;2(7514):495–497. [PubMed]
  • Czervionke RL, Smith JB, Fry GL, Hoak JC, Haycraft DL. Inhibition of prostacyclin by treatment of endothelium with aspirin. Correlation with platelet adherence. J Clin Invest. 1979 May;63(5):1089–1092. [PMC free article] [PubMed]
  • Orme M. Aspirin all round? Br Med J (Clin Res Ed) 1988 Jan 30;296(6618):307–308. [PMC free article] [PubMed]
  • Rasmanis G, Vesterqvist O, Gréen K, Edhag O, Henriksson P. Effects of intermittent treatment with aspirin on thromboxane and prostacyclin formation in patients with acute myocardial infarction. Lancet. 1988 Jul 30;2(8605):245–247. [PubMed]
  • Lee TK, Chen YC, Lien IN, Liu MC, Huang ZS. Inhibitory effect of acetylsalicylic acid on platelet function in patients with completed stroke or reversible ischemic neurologic deficit. Stroke. 1988 May;19(5):566–570. [PubMed]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press